PLASMA CELL LEUKEMIA
Clinical trials for PLASMA CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for PLASMA CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug may reduce dangerous side effects of stem cell transplants in older patients
Disease control OngoingThis early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for long-term immune-suppressing medications after a stem cell transplant. The trial involves 32 older adults (age 60+) with certain…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
Lab tests aim to match right drug to each myeloma patient
Knowledge-focused OngoingThis study explores whether using lab tests that screen many drugs at once, along with genetic information, can help doctors choose the best treatment for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. The goal is to see i…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 06:49 UTC
-
Multiple myeloma drug dose study canceled before starting
Knowledge-focused TerminatedThis study was planned to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not been cured by earlier treatments. It was a phase 1 trial, meaning it was the first step in testing the drug in humans. However, the study was withdra…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC